Cost Effectiveness of ambrisentan (Volibris®) in the treatment of patients with Functional Class II or III pulmonary arterial hypertension.
|October 2008||February 2009|
A summary of the report that was prepared by the National Centre for Pharmacoeconomics and submitted to the HSE is included in the attached document.
In accordance with the Health Act (Pricing and Supply of Medical Goods) 2013 (section 18(4)), the HSE has requested the NCPE to re-examine the cost effectiveness of ambrisentan (Volibris®).
|27/05/2014||04/07/2014||Full Pharmacoeconomic Evaluation not Recommended.|